Education
About Us
Working with TipRanks
Follow Us
Renalytix Plc (RNLXY)
:RNLXY
Top Page
Renalytix
(OTC:RNLXY)
Rating:35Underperform
Price Target:―
Renalytix (RNLXY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.21M
Dividend YieldN/A
Average Volume (3M)56.93K
Price to Earnings (P/E)―
Beta (1Y)-0.12
Revenue Growth-18.70%
EPS Growth49.24%
CountryUS
Employees60
SectorHealthcare
Sector Strength44
IndustryHealthcare Providers & Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding165,603,010
10 Day Avg. Volume51,855
30 Day Avg. Volume56,926
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Renalytix Business Overview & Revenue Model
Company DescriptionRenalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.
How the Company Makes MoneyRenalytix generates revenue primarily through the sale of its diagnostic products and services to healthcare providers, hospitals, and clinical laboratories. The company's flagship product, KidneyIntelX, is a diagnostic platform that uses machine learning algorithms to assess the risk of kidney disease progression in patients. Revenue is derived from testing fees charged for each use of the KidneyIntelX platform. Additionally, Renalytix engages in partnerships with pharmaceutical companies and healthcare organizations to leverage its technology in drug development and clinical trials, which provides additional revenue streams. Strategic collaborations and licensing agreements also contribute to the company's financial performance, supporting the broader adoption of its diagnostic solutions.
Renalytix Earnings Call Summary
Earnings Call Date:Jun 17, 2025
(Q2-2025)
| % Change Since: -5.00%|
Next Earnings Date:Nov 04, 2025
Earnings Call Sentiment Positive
The call highlights significant achievements such as FDA approval, Medicare reimbursement, and strong revenue growth forecasts. However, challenges remain in scaling operations and international expansion.Q2-2025 Updates
Positive Updates
FDA Approval and Medicare Reimbursement
Renalytix achieved the first-ever FDA-approved breakthrough designation prognostic test for kidney disease, with full Medicare reimbursement at $950 per test. This positions KidneyIntelX in a unique and uncontested market.
Revenue Growth and Forecast
The company is confident in achieving $3.2 million revenue for the current fiscal year, with forecasts of $8.4 million next year and $17 million thereafter. Renalytix has delivered on a 20% quarter-on-quarter revenue growth post-funding.
Commercial Testing Volume Increase
Commercial testing volume increased significantly from 60% to 82% in the prior period.
Cost Reductions Achieved
Renalytix has achieved a 50% reduction in admin fees, alongside other significant cost reductions.
Operational Improvements
Test turnaround times have improved to under seven days, and 95% of Medicare claims are now paid in under 30 days, enhancing cash flow.
Strategic Partnerships and Market Expansion
Renalytix is developing strategic partnerships and expanding its market reach, including collaborations with ACPNY hospital system and other potential pharma partnerships.
Negative Updates
Dependency on Small Sales Team
The company is currently operating with a small sales team, which may limit rapid market expansion.
Limited Resources for International Expansion
Despite the potential for global expansion, Renalytix lacks the resources to enter international markets beyond the U.S. at this time.
Challenges in Scaling
The company admits challenges in scaling, such as needing additional distribution capacity and strategic partnerships to reach broader market penetration.
Company Guidance
In the Renalytix investor presentation, Executive Chairman Julian Baines outlined key growth metrics and future projections for the company. The fiscal year 2025 revenue is forecasted at $3.2 million, with expectations to rise to $8.4 million in the following year and $17 million subsequently. The company has achieved a 20% quarter-on-quarter revenue growth post-funding and has managed a 50% reduction in admin fees. Currently, 95% of Medicare claims are paid in under 30 days, and Medicare covers 52% of the tests at $950 each. Renalytix has expanded its customer base to over 800 independent ordering physicians and has processed over 15,000 clinical test results. The company's testing cancellation rate has significantly decreased from 24% to 8%, and the average turnaround time for test results has improved to under seven days. With cash reserves of $9.2 million and ongoing cost reductions, the business is strategically positioned for sustained growth, focusing heavily on expanding its hospital system partnerships and insurance coverage to further drive revenue and market penetration.Renalytix Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | ― | ― | ― | ― | ― |
| Gross Profit | 156.00K | 720.00K | 874.00K | 687.00K | ― |
| EBITDA | -33.09M | -45.10M | -52.69M | -33.69M | -9.77M |
| Net Income | -33.46M | -45.61M | -41.44M | -31.01M | -9.84M |
Balance Sheet | |||||
| Total Assets | 7.97M | 30.63M | 50.06M | 78.58M | 20.92M |
| Cash, Cash Equivalents and Short-Term Investments | ― | ― | ― | ― | ― |
| Total Debt | 8.54M | 12.12M | 12.34M | 0.00 | 255.00K |
| Total Liabilities | 15.83M | 23.66M | 19.46M | 7.12M | 4.97M |
| Stockholders Equity | ― | ― | ― | ― | ― |
Cash Flow | |||||
| Free Cash Flow | -30.11M | -34.09M | -46.59M | -29.17M | -10.33M |
| Operating Cash Flow | -30.11M | -34.09M | -45.92M | -28.40M | -9.52M |
| Investing Cash Flow | ― | ― | ― | ― | ― |
| Financing Cash Flow | ― | ― | ― | ― | ― |
Renalytix Technical Analysis
Negative
0.19
Price Trends
0.19
Negative
0.21
Negative
0.20
Negative
Market Momentum
>-0.01
Positive
46.23
Neutral
55.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNLXY, the sentiment is Negative. The current price of 0.19 is above the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.19, and below the 200-day MA of 0.20, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.23 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNLXY.
Renalytix Risk Analysis
Renalytix disclosed 91 risk factors in its most recent earnings report. Renalytix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Renalytix Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $36.57M | ― | -2.12% | ― | 12.82% | 96.46% | |
52 Neutral | $7.47B | -0.04 | -63.86% | 2.34% | 16.17% | 0.25% | |
49 Neutral | $95.21M | ― | -58.89% | ― | ― | ― | |
46 Neutral | $37.87M | ― | -70.06% | ― | 146.47% | 57.85% | |
45 Neutral | $43.03M | ― | -75.66% | ― | ― | -31.16% | |
38 Underperform | $31.90M | ― | -86.78% | ― | ― | -2.37% | |
35 Underperform | $32.21M | ― | ― | -18.70% | 49.24% |
* Healthcare Sector Average
Performance Comparison
RNLXY
Renalytix
0.18
-0.11
-37.93%
RMTI
Rockwell Med
1.10
-0.82
-42.71%
RNTX
Rein Therapeutics
1.42
-1.32
-48.18%
LTRN
Lantern Pharma
3.99
-0.42
-9.52%
GBIO
Generation Bio
0.41
-2.47
-85.76%
CNTB
Connect Biopharma Holdings
1.86
0.59
46.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.